Table 2. Reported clinical trials combining LDFRT with chemotherapy in solid tumors.

Clinical trial parameters	Induction regimen	Phase I					Phase II
Site	Locally advanced SCCHN	Recurrent ovarian fallopian tube/peritoneal cancers	Locally advanced pancreatic or small bowel adenocarcinoma	Stage III/IV endometrial carcinoma	Recurrent/progressive GBM	Stage IIA/B-IIIA breast cancer	Recurrent NSCLC
Design	Paclitaxel (225 mg/m2), carboplatin (area under the curve of 6), and four 80-cGy fractions of radiotherapy (two each on days 1 and 2). This sequence was repeated on days 22 and 23	One of three dose levels of docetaxel (20, 25, or 30 mg/m2) weekly with concurrent LDFRT given as 60 cGy bid 2 days weekly for 6 weeks	Gemcitabine 1,250 mg/m2 at 10 mg/m2/min on days 1 and 8 of a 3-week cycle. LDFRT at two dose levels: 60 cGy per fraction and 70 cGy per fraction on days 1, 2, 8, and 9 for 4 weeks	Six weekly cycles of FD-CDDP (40 mg/m2, maximum 70 mg IV) + LDFRT at 0.5 Gy/fx (total 3 Gy) and 0.75 Gy/fx (total 4.5 Gy)	LDFRT 0.3 Gy twice daily with cisplatin and fotemustine if progressing on temozolomide, or 0.4 Gy twice daily with temozolomide if recurrent	LDFRT 0.4 Gy/per fraction, 2 fractions per day, for 2 days, every 21 days for 6-8 cycles) with non-pegylated liposomal doxorubicin and docetaxel	Pemetrexed (500mg/m2 IV) and concurrent LDFRT (40cGy bid on days 1 and 2) was repeated fourfold every 21 days
Duration	5 years	2 years	37 months	27 months	20 months		2 years
Recruitment	40	13	10	12	26	10	19
References	Arnold et al. (34); Gleason Jr et al. (35)	Kunos et al. (36)	Regine et al. (37)	Wrenn et al. (38)	Balducci et al. (39)	Nardone et al. (40)	Mantini et al. (41)

LDFRT, Low Doses Fractionated Radiation Therapy.